Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human inhaled MMI-0100 study in healthy volunteers
NL-OMON40896Phase 1Active, not recruiting
- Sponsor
- Moerae Matrix, Inc
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1 trial of MMI-0100 in idiopathic pulmonary fibrosis (IPF) and fibrosis (2 arms), sponsored by Moerae Matrix, Inc. Primary endpoints: Safety and tolerability, Systemic pharmacokinetics of MMI-0100 and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
MMI-0100
03
Conditions
idiopathic pulmonary fibrosis (IPF)fibrosis
Beyond the preview
Go deeper on NL-OMON40896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40896.